Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of TCC1727 in combination with benmelstobart, olaparib, or topotecan in advanced solid tumors
CTR20253887Phase 2Active
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TCC1727 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), endometrial cancer (EC), ovarian cancer, primary peritoneal cancer (PPC), sponsored by Beijing Tide Pharmaceutical Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
TCC1727
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)endometrial cancer (EC)ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20253887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253887.